PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib   Onartuzumab in Advanced Non-Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

(2014) H. Koeppen et al.   CLINICAL CANCER RESEARCH

p21-Activated protein kinases and their emerging roles in glucose homeostasis

(2013) Yu-ting Alex Chiang et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Pak1 Kinase Links ErbB2 to  -Catenin in Transformation of Breast Epithelial Cells

(2013) L. E. Arias-Romero et al.   CANCER RESEARCH

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

(2013) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

P21-Activated Kinase 1 (PAK1) as a Therapeutic Target in BRAF Wild-Type Melanoma

(2013) Christy C. Ong et al.   JNCI-Journal of the National Cancer Institute

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

(2013) M. Merchant et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

p21-Activated Kinase 1 Is Required for Efficient Tumor Formation and Progression in a Ras-Mediated Skin Cancer Model

(2012) H. Y. Chow et al.   CANCER RESEARCH

Molecular Pathways: Targeting P21-Activated Kinase 1 Signaling in Cancer--Opportunities, Challenges, and Limitations

(2012) J. Eswaran et al.   CLINICAL CANCER RESEARCH

Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events

(2012) J. Liu et al.   GENOME RESEARCH

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Active PI3K Pathway Causes an Invasive Phenotype Which Can Be Reversed or Promoted by Blocking the Pathway at Divergent Nodes

(2012) Jeffrey J. Wallin et al.   PLoS One

A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma

(2011) Lutz Eric et al.   ANNALS OF SURGERY

Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition

(2011) K. P. Hoeflich et al.   CANCER RESEARCH

c-Met Is a Marker of Pancreatic Cancer Stem Cells and Therapeutic Target

(2011) Chenwei Li et al.   GASTROENTEROLOGY

Inhibition or Ablation of p21-activated Kinase (PAK1) Disrupts Glucose Homeostatic Mechanismsin Vivo

(2011) Zhanxiang Wang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Pancreatic cancer

(2011) Audrey Vincent et al.   LANCET

PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling

(2011) Y Shrestha et al.   ONCOGENE

Tyrosine 23 Phosphorylation-Dependent Cell-Surface Localization of Annexin A2 Is Required for Invasion and Metastases of Pancreatic Cancer

(2011) Lei Zheng et al.   PLoS One

Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells

(2011) C. C. Ong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence

(2011) D. V. T. Catenacci et al.   Cancer Discovery

Signalling to cancer cell invasion through PAK family kinases

(2010) Andrew Whale   Frontiers in Bioscience-Landmark

PAK4: a pluripotent kinase that regulates prostate cancer cell adhesion

(2010) C. M. Wells et al.   JOURNAL OF CELL SCIENCE

β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation

(2010) Felipe C Geyer et al.   MODERN PATHOLOGY

Pancreatic Cancer

(2010) Manuel Hidalgo   NEW ENGLAND JOURNAL OF MEDICINE

PAK1 and PAK2 have different roles in HGF-induced morphological responses

(2009) Michael D. Bright et al.   CELLULAR SIGNALLING

DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer

(2009) Christine A. Iacobuzio-Donahue et al.   JOURNAL OF CLINICAL ONCOLOGY

PAK1 interacts with β-catenin and is required for the regulation of the β-catenin signalling pathway by gastrins

(2008) Hong He et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

(2008) H. Jin et al.   CANCER RESEARCH

An Isoform-Selective, Small-Molecule Inhibitor Targets the Autoregulatory Mechanism of p21-Activated Kinase

(2008) Sean W. Deacon et al.   CHEMISTRY & BIOLOGY

The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†

(2008) Adrian J. Folkes et al.   JOURNAL OF MEDICINAL CHEMISTRY

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

(2008) S. Jones et al.   SCIENCE